(1) KRS 217.5401 to 217.5408 shall not: (a) Expand the coverage required of an insurer; (b) Affect the requirements for insurance coverage of routine patient costs for patients involved in approved cancer clinical trials; (c) Require a health plan, third -party administrator, or governmental agency to pay costs associated with the use, care, or treatment of an eligible patient with an investigational drug, biological product, or device; or (d) Require a hospital or health facility to provide new or additional services. (2) A health plan, third -party administrator, or governmental age ncy may provide coverage for the cost of an investigational drug, biological product, or device or the cost of services related to the use of an investigational drug, biological product, or device under KRS 217.5401 to 217.5408. (3) A hospital or health fa cility may approve the use of an investigational drug, biological product, or device in the hospital or health facility.
‹ Prev All Kentucky sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.